60 Degrees Pharma reports positive safety update from Phase 2 babesiosis study
60 Degrees Pharma (NASDAQ:SXTP) reported that an independent Data Safety Monitoring Board found no safety concerns in the first six patients in its Phase 2 B-Free chronic babesiosis study and recommended trial continuation.

-640x360.webp&w=3840&q=75)








_1431612_640x360_2505289283565-640x360.webp&w=3840&q=75)
